Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Glaukos Corporation

GKOSNYSEEQUITYCurrent

Changes in Beneficial Ownership

Filed Mar 19, 2026Accepted Mar 19, 2026, 4:10 PM EDTFiling CIK 1644557Accession 0001644557-26-000014
Share

Structured filing — 4

form4-03192026_040303.xml

Open full document ↗

Filing details

Report period
2026-03-16
Issuer
GLAUKOS Corp
Issuer CIK
0001192448
Trading symbol
GKOS

Reporting owner 1

Name
Burns Thomas William
Reporting owner CIK
0001644557
Relationship
Director · Officer
Officer title
CHAIRMAN & CEO
Address
C/O GLAUKOS CORPORATION, ONE GLAUKOS WAY, ALISO VIEJO, CA, 92656

Non-derivative transactions

Non-derivative transactions · 1 reported row
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnership
Common Stock2026-03-16F · Form 42,801[F1]D98.94242,451[F2]D
Table key
F · Form 4
Securities delivered or withheld for exercise price or tax liability under Rule 16b-3
D
Direct

Non-derivative holdings

Non-derivative holdings · 5 reported rows
SecurityAmount ownedOwnershipNature of ownership
Common Stock961,285IThrough the Burns Family Trust
Common Stock238,107IThrough the Burns Annuity Trust
Common Stock120,000IThrough the Burns Charitable Remainder Trust
Common Stock100,000IThrough the Thomas W. Burns Irrevocable Trust
Common Stock100,000IThrough the Janet M. Burns Irrevocable Trust
Table key
I
Indirect

Footnotes

F1
Consists of shares withheld by the Issuer with respect to tax withholding obligations of the Reporting Person upon vesting and delivery of shares of common stock underlying restricted stock units previously granted by the Issuer on March 14, 2024.↩ 1
F2
Includes 64,610 restricted stock units that have not yet vested or been delivered to the Reporting Person.↩ 1

Signature 1

Signed
Diana Scherer, Attorney-in-Fact
Date
2026-03-19

Company context

Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel,

Current securities

Recent company filings

  1. SCHEDULE 13G/A - filed by Janus Henderson Group Ltd. regarding GLAUKOS CorpNov 16, 2026
  2. Regulation FD DisclosureNov 6, 2026
  3. 10-Q filingOct 28, 2026
  4. Results of Operations and Financial Condition · Regulation FD DisclosureOct 28, 2026
  5. 144 filingSep 16, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.